61
Participants
Start Date
July 27, 2020
Primary Completion Date
August 25, 2025
Study Completion Date
August 25, 2025
INCAGN02385
INCAGN02385 administered intravenously
INCAGN02390
INCAGN02390 administered intravenously
INCMGA00012.
INCMGA00012 administered intravenously
Nyu Langone Laura and Isaac Perlmutter Cancer Center, New York
Hillman Cancer Center, Pittsburgh
Penn State Hershey Cancer Institute, Hershey
Cancer Center For Blood Disorders A Division of American Oncology Partners P.A, Bethesda
Carolina Bio Oncology, Huntersville
University of Miami Sylvester Comprehensive Cancer Center, Miami
H Lee Moffitt Cancer Center and Research, Tampa
University of Iowa, Iowa City
Washington University, St Louis
The Angeles Clinic and Research Institute, Los Angeles
University of Washington-Seattle Cancer Care Alliance, Seattle
John Theurer Cancer Center, Hackensack University Medical Center, Hackensack
Melanoma Institute Australia, Wollstonecraft
Greenslopes Private Hospital, Brisbane
Flinders Medical Centre, Bedford Park
Box Hill Hospital, Box Hill
One Clinical Research, Nedlands
Lead Sponsor
Incyte Corporation
INDUSTRY